Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Merck's Capital Expenditure for the
three
months ended in Dec. 2023 was $-989.00 Mil. Its Operating Income for the
three
months ended in Dec. 2023 was $-1,713.00 Mil.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
Merck Capex-to-Operating-Income Historical Data
The historical data trend for Merck's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Merck Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Capex-to-Operating-Income
0.43
0.80
0.34
0.24
1.31
Merck Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Capex-to-Operating-Income
0.33
0.27
-
0.15
-
Competitive Comparison
For the Drug Manufacturers - General subindustry, Merck's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck Capex-to-Operating-Income Distribution
For the Drug Manufacturers industry and Healthcare sector, Merck's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Merck's Capex-to-Operating-Income falls into.
Merck Capex-to-Operating-Income Calculation
Merck's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Merck Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of Merck's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRK has been successfully added to your 